Orgenesis subsidiary sells five OMPULs to Germfree for $8.34M, enters 10-year collaboration

Orgenesis Inc.

Orgenesis Maryland sells five Octomera Mobile Processing Units & Labs (OMPULs) to Germfree for $8.34M.
Germfree gets a worldwide royalty-free license to Orgenesis' Quality Management Systems Framework (OQMSF).
Germfree will exclusively manufacture and distribute OMPULs for Orgenesis worldwide for 10 years.
Each party pays the other a 15% commission on Net Sales of OMPULs/services when customer is introduced.
Strategic Collaboration Committee with 3 members from each party to oversee joint marketing and sales pipeline.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Orgenesis Inc. entered into Asset Purchase and Strategic Collaboration Agreement with Griffin Fund 3 BIDCO, Inc., ("Germfree") valued at aggregate purchase price of $8,340,000 (effective 2024-04-05).

Action: entry
Agreement: asset purchase
Counterparty: Griffin Fund 3 BIDCO, Inc., ("Germfree")
Value: aggregate purchase price of $8,340,000
Effective: 2024-04-05

Exact text from the filing

On April 5, 2024, Orgenesis Maryland LLC (“Orgenesis Maryland”), a wholly-owned subsidiary of Orgenesis Inc., entered into an Asset Purchase and Strategic Collaboration Agreement (the “Purchase Agreement”) with Griffin Fund 3 BIDCO, Inc., (“Germfree"), for the sale by Orgenesis Maryland of five Octomera Mobile Processing Units and Labs (“OMPULs”) to Germfree

View on SEC.gov

Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-24-014329

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.